This inventor holds 5 USPTO granted patents and 1 published patent application. Top assignees: Imtm Gmbh, Institut Fur Medizintechnologie Magdeburg (Imtm) Gmbh. Active years: 2007-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2007-2010
Title: The Innovations of Uwe Lendeckel: Pioneering Research in Enzyme Inhibition
Introduction
Uwe Lendeckel, an accomplished inventor based in Magdeburg, Germany, has made significant contributions to the field of biopharmaceuticals with his innovative work. With a total of five patents to his name, Lendeckel has focused his research on the combined use of enzyme inhibitors, promising advancements in the treatment of various medical conditions, including arteriosclerosis and dermatological diseases.
Latest Patents
Among his most notable recent patents is the invention related to the combined use of enzyme inhibitors and pharmaceutical compositions thereof. This innovative approach provides combinations of dipeptidyl peptidase IV (DP IV) inhibitors alongside enzymes that share similar substrate specificity. These combinations aim to achieve more than additive to superadditive inhibition for the treatment of arteriosclerosis, type I allergic reactions, and dermatological diseases characterized by follicular and epidermal hyperkeratoses.
Another important patent involves the use of enzyme inhibitors of aminopeptidase N and dipeptidyl peptidase IV. This invention outlines a process to inhibit DNA synthesis, crucial for the proliferation of human sebaceous cells. By administering inhibitors of APN and DP IV, Lendeckel's research presents a promising therapeutic avenue for managing dermatological conditions associated with sebaceous hyperproliferation and altered differentiation.
Career Highlights
Uwe Lendeckel's career has been marked by his association with esteemed organizations such as IMTM GmbH and the Institute for Medical Technology Magdeburg (imtm) GmbH. His experience in these institutions has aided in the development of his patents and has fostered important research in enzyme inhibition, significantly impacting the pharmaceutical industry.
Collaborations
Throughout his career, Lendeckel has collaborated with notable colleagues, including Siegfried Ansorge and Klaus Neubert. These partnerships have facilitated the exchange of knowledge, enhancing Lendeckel's innovative solutions to complex medical challenges.
Conclusion
In conclusion, Uwe Lendeckel stands out as an influential inventor in the realm of enzyme inhibition and biopharmaceuticals. His latest patents reflect a commitment to advancing medical treatments through innovation, while his collaborations and career milestones underscore the impact of teamwork in scientific research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile